Successful treatment of fulminant hepatitis B during pregnancy.
We here report the use of lamivudine 100 mg daily in a young pregnant woman (24th week of gestation) with fulminant hepatic failure due to acute HBV infection. After initiation of oral lamivudine (100 mg/d), ALT levels rapidly decreased from 5046 U/L to normal values within five weeks. HBe seroconversion occured three weeks after treatment start, followed by HBs seroconversion within less than six months. A preterm female baby was delivered at gestational week 29 (weight 1000 gr) (five weeks after start of lamivudine). The infant received simultaneous active and passive HBV immunisation within 12 hours after delivery. The neonatal check-up revealed meconium ileus which was successfully treated by surgery. At last presentation 241 days after initiation of treatment, both mother and infant showed stable HBs-seroconversion (anti-HBs 169 IU/mL and > 1000 IU/L, respectively). Therefore, lamivudine therapy was withdrawn. This case suggests that oral nucleos(t)ides may be safely used in pregnant patients with fulminant hepatitis B potentially preventing liver transplantation and interruption of pregnancy.
Potthoff
A
A
Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule, Medizinische Hochschule, Carl-Neuberg Str. 1, 30171 Hannover.
Rifai
K
K
Wedemeyer
H
H
Deterding
K
K
Manns
M
M
Strassburg
C
C
D019380:Anti-HIV Agents / Q000008:administration & dosage; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D016896:Treatment Outcome; D055815:Young Adult
D019380:Anti-HIV Agents; D019259:Lamivudine